{ "run": { "id": "cmnqz7omq00zyp658hm61d116", "region": "BR", "assetId": "cmlr6u1zd0013qj3287tf871h", "ticker": "RDOR3", "snapshotId": "cmnqz7omc00zup6585t3n4wae", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T04:27:49.486Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnqz7omc00zup6585t3n4wae", "assetId": "cmlr6u1zd0013qj3287tf871h", "asOf": "2026-04-08T21:30:33.000Z", "snapshot": { "asOf": "2026-04-08T21:30:33.000Z", "quote": { "asOf": "2026-04-08T21:30:33.000Z", "open": 41.92, "price": 40.61, "dayLow": 40.47, "volume": 9417100, "dayHigh": 42.3, "currency": "BRL", "prevClose": 40.72, "week52Low": 28.36, "week52High": 48.41 }, "fundamentals": { "pe": 19.11688556230288, "beta": 0, "epsTTM": 2.1242562, "fcfTTM": -3502744000, "growth": { "epsYoy": 4.1815424, "revenueYoy": 3.336992 }, "sector": "Saúde", "margins": { "net": 0.08691878, "gross": 0.21854274, "operating": 0.17740783 }, "website": "https://www.rededorsaoluiz.com.br/", "industry": "Serviços Médicos Hospitalares", "pegRatio": 0.04512165, "ebitdaTTM": 11718032000, "forwardPe": 0, "marketCap": 89835112071, "totalCash": 40560497000, "totalDebt": 67367576000, "debtEquity": 3.1158276, "quickRatio": 2.7283673, "revenueTTM": 55725850000, "companyName": "Rede D'Or Sao Luiz SA", "priceToBook": 4.226825, "currentRatio": 2.79043, "dividendYield": 0.1012463142083231, "returnOnAssets": 0.04545931, "returnOnEquity": 0.22402312, "analystOpinions": 0, "businessSummary": "A Rede D'Or São Luiz S.A., listada na B3 sob o ticker RDOR3, foi fundada em 1977 e atua no setor de saúde privada no Brasil. A companhia opera rede hospitalar e serviços associados, com crescimento sustentado por expansão orgânica e aquisições.\n\nO grupo atua em hospitais gerais e especializados, oncologia, diagnóstico e serviços complementares de saúde, além de integração com operadora de planos após movimentos societários recentes. O modelo de negócio combina prestação de serviços médico-hospitalares e gestão de ativos assistenciais em grande escala.\n\nNo ambiente competitivo, a empresa disputa mercado com outras redes hospitalares e grupos integrados de saúde suplementar, com foco em complexidade assistencial e ocupação de leitos. A dinâmica competitiva envolve qualidade clínica, eficiência operacional, expansão regional e capacidade de investimento.\n\nA atuação geográfica abrange difere…", "enterpriseValue": 118195634000, "analystTargetLow": 0, "analystTargetHigh": 0, "analystTargetMean": 0, "fullTimeEmployees": 67285, "sharesOutstanding": 2289292500, "enterpriseToEbitda": 10.086645, "analystTargetMedian": 0, "enterpriseToRevenue": 2.1210198, "operatingCashflowTTM": 538367000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T04:27:49.477Z" }, "results": [ { "id": "cmnqz7omt0102p658txv8mk1e", "runId": "cmnqz7omq00zyp658hm61d116", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"RDOR3\",\"currency\":\"BRL\",\"current_price\":40.61,\"target_price_6m\":43.0,\"target_price_12m\":45.5,\"recommendation\":\"BUY\",\"confidence\":0.6,\"thesis_bullets\":[\"Largest private hospital network in Brazil with scale advantages\",\"ROE of 22.4% supports premium valuation vs healthcare peers\",\"EV/EBITDA at 10.1x reasonable for defensive healthcare compounder\",\"High leverage (D/E 3.1x) and negative FCF are key near-term concerns\",\"Dividend yield ~10% provides income cushion amid macro volatility\"],\"key_drivers\":[{\"driver\":\"Hospital bed occupancy rates and case-mix complexity\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin expansion from operating leverage on scale\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Integration of SulAmérica health plan vertical\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"High gross debt of BRL 67.4B vs BRL 40.6B cash\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Negative FCF TTM of BRL -3.5B from heavy capex/M&A\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Brazilian interest rate cycle impacting cost of debt\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Revenue growth moderating to 3.3% YoY\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Supplementary health plan penetration growth in Brazil\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory environment for private healthcare\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Sustained negative FCF if capex discipline does not improve\",\"Rising Selic rate increases refinancing cost on BRL 67B debt\",\"Regulatory changes to private health plan reimbursement rates\",\"Integration risk from SulAmérica and ongoing acquisitions\",\"Economic slowdown reducing demand for premium healthcare services\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":0.19,\"wacc\":0.13,\"terminal_multiple\":10.0},\"scenarios\":{\"bear\":{\"target_price\":34.0,\"prob\":0.2,\"notes\":\"Margin compression from debt servicing costs and slower volumes.\"},\"base\":{\"target_price\":45.5,\"prob\":0.55,\"notes\":\"Gradual margin expansion to 19%, moderate EPS growth of 10-12%.\"},\"bull\":{\"target_price\":54.0,\"prob\":0.25,\"notes\":\"Successful vertical integration drives synergies, deleveraging accelerates.\"}},\"method_notes\":\"Blended valuation: forward P/E (~17-19x on FY27E EPS ~2.50) and EV/EBITDA (10-11x on EBITDA growth ~8%). ROE of 22% justifies P/B of ~4.2x. Key tension: strong profitability vs high leverage and negative FCF. 12M target implies ~12% return supporting BUY. Confidence capped at 0.60 due to FCF concerns and macro sensitivity. PEG ratio in snapshot (0.045) appears anomalous and was not used. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained negative FCF if capex discipline does not improve", "Rising Selic rate increases refinancing cost on BRL 67B debt", "Regulatory changes to private health plan reimbursement rates", "Integration risk from SulAmérica and ongoing acquisitions", "Economic slowdown reducing demand for premium healthcare services" ], "ticker": "RDOR3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Gradual margin expansion to 19%, moderate EPS growth of 10-12%.", "target_price": 45.5 }, "bear": { "prob": 0.2, "notes": "Margin compression from debt servicing costs and slower volumes.", "target_price": 34 }, "bull": { "prob": 0.25, "notes": "Successful vertical integration drives synergies, deleveraging accelerates.", "target_price": 54 } }, "confidence": 0.6, "assumptions": { "wacc": 0.13, "revenue_cagr_3y": 0.08, "terminal_multiple": 10, "ebit_margin_target": 0.19 }, "key_drivers": [ { "driver": "Hospital bed occupancy rates and case-mix complexity", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion from operating leverage on scale", "impact": "HIGH", "direction": "POS" }, { "driver": "Integration of SulAmérica health plan vertical", "impact": "HIGH", "direction": "POS" }, { "driver": "High gross debt of BRL 67.4B vs BRL 40.6B cash", "impact": "HIGH", "direction": "NEG" }, { "driver": "Negative FCF TTM of BRL -3.5B from heavy capex/M&A", "impact": "HIGH", "direction": "NEG" }, { "driver": "Brazilian interest rate cycle impacting cost of debt", "impact": "MED", "direction": "NEG" }, { "driver": "Revenue growth moderating to 3.3% YoY", "impact": "MED", "direction": "NEG" }, { "driver": "Supplementary health plan penetration growth in Brazil", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory environment for private healthcare", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended valuation: forward P/E (~17-19x on FY27E EPS ~2.50) and EV/EBITDA (10-11x on EBITDA growth ~8%). ROE of 22% justifies P/B of ~4.2x. Key tension: strong profitability vs high leverage and negative FCF. 12M target implies ~12% return supporting BUY. Confidence capped at 0.60 due to FCF concerns and macro sensitivity. PEG ratio in snapshot (0.045) appears anomalous and was not used. Not investment advice.", "current_price": 40.61, "recommendation": "BUY", "thesis_bullets": [ "Largest private hospital network in Brazil with scale advantages", "ROE of 22.4% supports premium valuation vs healthcare peers", "EV/EBITDA at 10.1x reasonable for defensive healthcare compounder", "High leverage (D/E 3.1x) and negative FCF are key near-term concerns", "Dividend yield ~10% provides income cushion amid macro volatility" ], "target_price_6m": 43, "target_price_12m": 45.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 38483, "createdAt": "2026-04-09T04:27:49.486Z", "usage": { "inputTokens": 3763, "outputTokens": 1639, "costUsd": 0.05979 } }, { "id": "cmnqz7omt0105p658n1uarpl5", "runId": "cmnqz7omq00zyp658hm61d116", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"RDOR3\",\n \"currency\": \"BRL\",\n \"current_price\": 40.61,\n \"target_price_6m\": 42.5,\n \"target_price_12m\": 45.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Moderate revenue growth from healthcare demand in Brazil.\",\n \"Stable operating margins due to scale and efficiency gains.\",\n \"High dividend yield supports income for investors.\",\n \"High debt levels increase financial risk in rate hikes.\",\n \"Regulatory and competitive pressures could limit upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Healthcare demand growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operational efficiency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt leverage\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory environment\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic conditions\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Acquisition strategy\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Dividend policy\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n ],\n \"risks\": [\"High debt increasing financial risk\", \"Regulatory changes in healthcare sector\", \"Economic downturn in Brazil\", \"Intense competition from peers\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.11,\n \"terminal_multiple\": 20\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 35.0, \"prob\": 0.2, \"notes\": \"Slower growth and margin pressure.\" },\n \"base\": { \"target_price\": 45.0, \"prob\": 0.6, \"notes\": \"Steady execution on plans.\" },\n \"bull\": { \"target_price\": 50.0, \"prob\": 0.2, \"notes\": \"Accelerated growth and efficiency.\" }\n },\n \"method_notes\": \"Valuation using DCF with growth and margin assumptions. BUY due to moderate upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Equity Research Model", "risks": [ "High debt increasing financial risk", "Regulatory changes in healthcare sector", "Economic downturn in Brazil", "Intense competition from peers" ], "ticker": "RDOR3", "currency": "BRL", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution on plans.", "target_price": 45 }, "bear": { "prob": 0.2, "notes": "Slower growth and margin pressure.", "target_price": 35 }, "bull": { "prob": 0.2, "notes": "Accelerated growth and efficiency.", "target_price": 50 } }, "confidence": 0.65, "assumptions": { "wacc": 0.11, "revenue_cagr_3y": 0.06, "terminal_multiple": 20, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Healthcare demand growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operational efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Debt leverage", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory environment", "impact": "MED", "direction": "NEG" }, { "driver": "Economic conditions", "impact": "HIGH", "direction": "NEG" }, { "driver": "Acquisition strategy", "impact": "MED", "direction": "POS" }, { "driver": "Dividend policy", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation using DCF with growth and margin assumptions. BUY due to moderate upside. Not investment advice.", "current_price": 40.61, "recommendation": "BUY", "thesis_bullets": [ "Moderate revenue growth from healthcare demand in Brazil.", "Stable operating margins due to scale and efficiency gains.", "High dividend yield supports income for investors.", "High debt levels increase financial risk in rate hikes.", "Regulatory and competitive pressures could limit upside." ], "target_price_6m": 42.5, "target_price_12m": 45 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 336, "createdAt": "2026-04-09T04:27:49.486Z", "usage": { "inputTokens": 2234, "outputTokens": 3564, "costUsd": 0.002122 } }, { "id": "cmnqz7omt0103p6582pizivh2", "runId": "cmnqz7omq00zyp658hm61d116", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_RDOR3\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"RDOR3\",\n \"currency\": \"BRL\",\n \"current_price\": 40.61,\n \"target_price_6m\": 43.50,\n \"target_price_12m\": 46.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.70,\n \"thesis_bullets\": [\n \"Market leader in Brazilian private healthcare with significant barriers to entry.\",\n \"SulAmérica integration provides unique vertical synergies and cross-selling opportunities.\",\n \"Strong ROE of 22.4% demonstrates efficient capital allocation despite high leverage.\",\n \"Negative FCF reflects heavy growth capex, which should normalize over time.\",\n \"Current EV/EBITDA of 10x is attractive relative to historical premium multiples.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"SulAmérica integration synergies\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate (Selic) trends affecting debt service\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Hospital bed occupancy rates\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical inflation (VCMH) vs. price adjustments\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Greenfield hospital expansions\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Dividend payout sustainability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"High financial leverage (Debt/Equity > 3x) increases vulnerability to sustained high interest rates.\",\n \"Regulatory changes in the Brazilian supplementary health sector (ANS).\",\n \"Integration risks and potential friction with other health insurance providers.\",\n \"Persistent negative free cash flow if capex does not yield expected returns.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.115,\n \"terminal_multiple\": 10.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 35.00,\n \"prob\": 0.25,\n \"notes\": \"Integration synergies fail to materialize and high interest rates pressure the leveraged balance sheet.\"\n },\n \"base\": {\n \"target_price\": 46.00,\n \"prob\": 0.55,\n \"notes\": \"Steady organic growth, successful SulAmérica integration, and stable operating margins.\"\n },\n \"bull\": {\n \"target_price\": 52.00,\n \"prob\": 0.20,\n \"notes\": \"Faster than expected deleveraging, margin expansion from operational leverage, and accretive M&A.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and EV/EBITDA multiple approach. Target price implies a ~13% upside, supporting a BUY rating. High leverage and negative FCF cap the upside to STRONG_BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "EquityResearch_RDOR3", "risks": [ "High financial leverage (Debt/Equity > 3x) increases vulnerability to sustained high interest rates.", "Regulatory changes in the Brazilian supplementary health sector (ANS).", "Integration risks and potential friction with other health insurance providers.", "Persistent negative free cash flow if capex does not yield expected returns." ], "ticker": "RDOR3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Steady organic growth, successful SulAmérica integration, and stable operating margins.", "target_price": 46 }, "bear": { "prob": 0.25, "notes": "Integration synergies fail to materialize and high interest rates pressure the leveraged balance sheet.", "target_price": 35 }, "bull": { "prob": 0.2, "notes": "Faster than expected deleveraging, margin expansion from operational leverage, and accretive M&A.", "target_price": 52 } }, "confidence": 0.7, "assumptions": { "wacc": 0.115, "revenue_cagr_3y": 0.06, "terminal_multiple": 10.5, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "SulAmérica integration synergies", "impact": "HIGH", "direction": "POS" }, { "driver": "Interest rate (Selic) trends affecting debt service", "impact": "HIGH", "direction": "NEG" }, { "driver": "Hospital bed occupancy rates", "impact": "MED", "direction": "POS" }, { "driver": "Medical inflation (VCMH) vs. price adjustments", "impact": "HIGH", "direction": "NEG" }, { "driver": "Greenfield hospital expansions", "impact": "MED", "direction": "POS" }, { "driver": "Dividend payout sustainability", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF and EV/EBITDA multiple approach. Target price implies a ~13% upside, supporting a BUY rating. High leverage and negative FCF cap the upside to STRONG_BUY. Not investment advice.", "current_price": 40.61, "recommendation": "BUY", "thesis_bullets": [ "Market leader in Brazilian private healthcare with significant barriers to entry.", "SulAmérica integration provides unique vertical synergies and cross-selling opportunities.", "Strong ROE of 22.4% demonstrates efficient capital allocation despite high leverage.", "Negative FCF reflects heavy growth capex, which should normalize over time.", "Current EV/EBITDA of 10x is attractive relative to historical premium multiples." ], "target_price_6m": 43.5, "target_price_12m": 46 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19249, "createdAt": "2026-04-09T04:27:49.486Z", "usage": { "inputTokens": 2474, "outputTokens": 852, "costUsd": 0.015172 } }, { "id": "cmnqz7omt0101p658at3badmi", "runId": "cmnqz7omq00zyp658hm61d116", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"RDOR3\",\"currency\":\"BRL\",\"current_price\":40.61,\"target_price_6m\":41.8,\"target_price_12m\":42.5,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Market-leading hospital platform supports resilient demand and pricing.\",\"Operating margin is solid, but free cash flow remains weak.\",\"Balance sheet carries sizable debt despite large cash buffer.\",\"Integration and capacity expansion can lift earnings gradually.\",\"Current valuation looks near fair versus growth and leverage.\"],\"key_drivers\":[{\"driver\":\"Hospital occupancy and case mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pricing with insurers\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Integration synergies\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"New beds and brownfield ramp\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Negative free cash flow\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Leverage and funding costs\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Execution on acquired assets\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Defensive healthcare demand\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Reimbursement pressure from payers\",\"Capex stays elevated longer\",\"Integration missteps dilute margins\",\"Regulatory or judicial healthcare changes\"],\"assumptions\":{\"revenue_cagr_3y\":8.5,\"ebit_margin_target\":18.5,\"wacc\":12.5,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":34,\"prob\":0.25,\"notes\":\"Margins compress and cash conversion stays weak.\"},\"base\":{\"target_price\":42.5,\"prob\":0.5,\"notes\":\"Steady volume growth and modest margin gains offset leverage.\"},\"bull\":{\"target_price\":50,\"prob\":0.25,\"notes\":\"Faster synergy capture and better payer mix expand earnings.\"}},\"method_notes\":\"Blended earnings-power and EV/EBITDA approach anchored on snapshot fundamentals and quote; no sell-side targets used. HOLD fits ~4.7% 12M upside with mixed evidence from strong franchise but weak FCF and leverage. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "gpt-5", "risks": [ "Reimbursement pressure from payers", "Capex stays elevated longer", "Integration missteps dilute margins", "Regulatory or judicial healthcare changes" ], "ticker": "RDOR3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady volume growth and modest margin gains offset leverage.", "target_price": 42.5 }, "bear": { "prob": 0.25, "notes": "Margins compress and cash conversion stays weak.", "target_price": 34 }, "bull": { "prob": 0.25, "notes": "Faster synergy capture and better payer mix expand earnings.", "target_price": 50 } }, "confidence": 0.62, "assumptions": { "wacc": 12.5, "revenue_cagr_3y": 8.5, "terminal_multiple": 10.5, "ebit_margin_target": 18.5 }, "key_drivers": [ { "driver": "Hospital occupancy and case mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Pricing with insurers", "impact": "HIGH", "direction": "POS" }, { "driver": "Integration synergies", "impact": "MED", "direction": "POS" }, { "driver": "New beds and brownfield ramp", "impact": "MED", "direction": "POS" }, { "driver": "Negative free cash flow", "impact": "HIGH", "direction": "NEG" }, { "driver": "Leverage and funding costs", "impact": "HIGH", "direction": "NEG" }, { "driver": "Execution on acquired assets", "impact": "MED", "direction": "NEG" }, { "driver": "Defensive healthcare demand", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended earnings-power and EV/EBITDA approach anchored on snapshot fundamentals and quote; no sell-side targets used. HOLD fits ~4.7% 12M upside with mixed evidence from strong franchise but weak FCF and leverage. not investment advice", "current_price": 40.61, "recommendation": "HOLD", "thesis_bullets": [ "Market-leading hospital platform supports resilient demand and pricing.", "Operating margin is solid, but free cash flow remains weak.", "Balance sheet carries sizable debt despite large cash buffer.", "Integration and capacity expansion can lift earnings gradually.", "Current valuation looks near fair versus growth and leverage." ], "target_price_6m": 41.8, "target_price_12m": 42.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0374ed85fe7e336c0069d72ce0f2548193b5d41f10bf491624", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 22174, "createdAt": "2026-04-09T04:27:49.486Z", "usage": { "inputTokens": 2459, "outputTokens": 1002, "costUsd": 0.018331 } }, { "id": "cmnqz7omt0104p6585hbnyb27", "runId": "cmnqz7omq00zyp658hm61d116", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"RDOR3\",\n \"currency\": \"BRL\",\n \"current_price\": 40.61,\n \"target_price_6m\": 44.2,\n \"target_price_12m\": 48.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.61,\n \"thesis_bullets\": [\n \"Leading hospital network drives scale and pricing power.\",\n \"M&A expansion sustains revenue growth in private healthcare.\",\n \"High dividend yield supports total returns for investors.\",\n \"Elevated debt and negative FCF limit financial flexibility.\",\n \"Stable margins offset by regulatory and macro headwinds.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Hospital network scale and M&A pipeline\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Demographic tailwinds in Brazilian healthcare\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High leverage and negative free cash flow\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating margin resilience\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Healthcare reimbursement pressures\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend sustainability at current payout\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Integration execution on acquisitions\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Brazil macro and competitive intensity\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Negative FCF persists amid capex needs\",\n \"Debt servicing costs rise with interest rates\",\n \"Regulatory shifts in health insurance\",\n \"Acquisition integration delays\",\n \"Intensifying competition from rivals\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 8.2,\n \"ebit_margin_target\": 18.0,\n \"wacc\": 9.5,\n \"terminal_multiple\": 12.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 34.5,\n \"prob\": 0.30,\n \"notes\": \"Higher rates and weak volume growth compress margins.\"\n },\n \"base\": {\n \"target_price\": 48.0,\n \"prob\": 0.50,\n \"notes\": \"Steady execution on expansion with stable leverage.\"\n },\n \"bull\": {\n \"target_price\": 57.0,\n \"prob\": 0.20,\n \"notes\": \"Stronger M&A synergies and volume acceleration.\"\n }\n },\n \"method_notes\": \"DCF using revenue CAGR 8.2%, 18% EBIT target, 9.5% WACC and 12x terminal EV/EBITDA; cross-checked with EV/EBITDA peers. 18% 12M upside supports BUY per rubric despite leverage risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Equity Research Model", "risks": [ "Negative FCF persists amid capex needs", "Debt servicing costs rise with interest rates", "Regulatory shifts in health insurance", "Acquisition integration delays", "Intensifying competition from rivals" ], "ticker": "RDOR3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on expansion with stable leverage.", "target_price": 48 }, "bear": { "prob": 0.3, "notes": "Higher rates and weak volume growth compress margins.", "target_price": 34.5 }, "bull": { "prob": 0.2, "notes": "Stronger M&A synergies and volume acceleration.", "target_price": 57 } }, "confidence": 0.61, "assumptions": { "wacc": 9.5, "revenue_cagr_3y": 8.2, "terminal_multiple": 12, "ebit_margin_target": 18 }, "key_drivers": [ { "driver": "Hospital network scale and M&A pipeline", "impact": "HIGH", "direction": "POS" }, { "driver": "Demographic tailwinds in Brazilian healthcare", "impact": "HIGH", "direction": "POS" }, { "driver": "High leverage and negative free cash flow", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operating margin resilience", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare reimbursement pressures", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend sustainability at current payout", "impact": "MED", "direction": "POS" }, { "driver": "Integration execution on acquisitions", "impact": "MED", "direction": "POS" }, { "driver": "Brazil macro and competitive intensity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using revenue CAGR 8.2%, 18% EBIT target, 9.5% WACC and 12x terminal EV/EBITDA; cross-checked with EV/EBITDA peers. 18% 12M upside supports BUY per rubric despite leverage risks. Not investment advice.", "current_price": 40.61, "recommendation": "BUY", "thesis_bullets": [ "Leading hospital network drives scale and pricing power.", "M&A expansion sustains revenue growth in private healthcare.", "High dividend yield supports total returns for investors.", "Elevated debt and negative FCF limit financial flexibility.", "Stable margins offset by regulatory and macro headwinds." ], "target_price_6m": 44.2, "target_price_12m": 48 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "8310a666-b864-915e-a515-772b1c1baa40", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 22760, "createdAt": "2026-04-09T04:27:49.486Z", "usage": { "inputTokens": 2798, "outputTokens": 2918, "costUsd": 0.052164 } } ] } }